FAKTOR OPTIONSSCHEIN - GENMAB | Delayed Deutsche Boerse AG 07:20:52 2024-06-21 am EDT | ||
| 14.72 EUR | +4.92% |
|
| Current month | -23.08% | ||
| 1 month | -34.01% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GENMAB A/S
| Date | Price | Change |
|---|---|---|
| 24-06-21 | 14.72 | +4.92% |
| 24-06-20 | 14.03 | +3.70% |
| 24-06-19 | 13.53 | -5.78% |
| 24-06-18 | 14.36 | +1.13% |
| 24-06-17 | 14.2 | -6.52% |
Delayed Quote Deutsche Boerse AG
Last update June 21, 2024 at 07:20 am EDT
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | GENMAB A/S |
| Issuer | 
BNP Paribas
|
| WKN | PE3GEN |
| ISIN | DE000PE3GEN2 |
| Date issued | 2022-06-02 |
| Strike | 1,797 kr |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 50 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 165.4 € |
|---|---|
| Lowest since issue | 13.41 € |
| Spread | 0.06 € |
| Spread % | 0.41% |
Company Profile
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Sector
-
Consensus: Genmab A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
1,797
DKK
Average target price
2,464
DKK
Spread / Average Target
+37.12%
- Stock Market
- Certificates
- Certificat
